University of SaskatchewanHARVEST
  • Login
  • Submit Your Research
  • About
    • About HARVEST
    • Guidelines
    • Browse
      • All of HARVEST
      • Communities & Collections
      • By Issue Date
      • Authors
      • Titles
      • Subjects
      • This Collection
      • By Issue Date
      • Authors
      • Titles
      • Subjects
    • My Account
      • Login
      JavaScript is disabled for your browser. Some features of this site may not work without it.
      View Item 
      • HARVEST
      • Electronic Theses and Dissertations
      • Graduate Theses and Dissertations
      • View Item
      • HARVEST
      • Electronic Theses and Dissertations
      • Graduate Theses and Dissertations
      • View Item

      Characterization of PIK3CD as a Cancer Drug Target

      Thumbnail
      View/Open
      SUMI-THESIS-2018.pdf (2.526Mb)
      Date
      2018-11-06
      Author
      Sumi, Sharmin Sultana
      Type
      Thesis
      Degree Level
      Masters
      Metadata
      Show full item record
      Abstract
      Peroxisome proliferator activated Receptors (PPARs) belong to the nuclear receptor super family and are ligand activated transcription factors regulating the expression of a wide variety of genes. On activation by a ligand, they bind to the PPAR-responsive regulatory elements (PPRE) and/or PPAR associated conserved motif (PACM) as obligate heterodimers with retinoid X recep¬tor (RXR). Recently, several reports have shown a consistent link between PPARγ activation and anti-tumorigenic effects in several tumor cell lines. Although several mechanisms have been proposed for this anti-tumorigenic effect on PPARγ activation, one of the potential mechanisms is the inhibition of telomerase activity and modulation of hTERT expression through the Myc/Mad/Max genes that are downstream targets of PPARγ. This mechanism is very interesting because hTERT expression is upregulated in 90% of the cancer cells. Our lab has computationally predicted over 1100 genes that are potentially regulated by PPARγ. Several of these targets have been identified in a genome-wide screen that was driven to identify factors that selectively kill hTERT overexpressing cells. My project involves validation of these targets using metabolic, proliferation and expression assays. Finally, we validated one potential target of PPARγ that can selectively kill hTERT overexpressing cells. These investigations have applications in cancer therapeutics.
      Degree
      Master of Science (M.Sc.)
      Department
      Pharmacy and Nutrition
      Program
      Pharmacy
      Supervisor
      Sakharkar, Meena
      Committee
      Vizeacoumar, Franco; Freywald, Andrew; Blackburn, David; Taghibiglou , Changiz
      Copyright Date
      October 2018
      URI
      http://hdl.handle.net/10388/11491
      Subject
      PPARγ
      PIK3CD
      hTERT
      Synthetic Dosages Lethality
      Collections
      • Graduate Theses and Dissertations
      University of Saskatchewan

      University Library

      © University of Saskatchewan
      Contact Us | Disclaimer | Privacy